BATTLEFIELD WOUND INFECTION PREVENTION AND TREATMENT (BWI P&T): BARRIER COMBINATION PRODUCT DEVELOPMENT
| Location: | Maryland |
|---|---|
| Posted: | Dec 3, 2025 |
| Due: | Jan 20, 2026 |
| Agency: | DEPT OF DEFENSE |
| Type of Government: | Federal |
| Category: |
|
| Solicitation No: | HT9427-26-RFI-BWI-PT |
| Publication URL: | To access bid details, please log in. |
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Sources Sought (Original)
- Original Published Date: Dec 03, 2025 11:44 am EST
- Original Response Date: Jan 20, 2026 02:00 pm EST
- Inactive Policy: 15 days after response date
- Original Inactive Date: Feb 04, 2026
-
Initiative:
- None
- Original Set Aside: No Set aside used
- Product Service Code:
- NAICS Code:
-
Place of Performance:
MD 21702USA
The Government is conducting market research to determine whether a commercial solution can be provided to meet requirements for battlefield wound infection prevention and treatment: barrier combination product. This market research may also assist with the further development and/or refinement of the requirements.
Objective and Purpose/Scope: DHA’s OPMED WPAC has a requirement to develop, deliver, and field medical products that address battlefield wounds and subsequent bacterial and fungal infections. The Battlefield Wound Infection Prevention and Treatment (BWI P&T) program is using a Family of Systems (FoS) approach that aims to develop multiple medical materiel solutions that are most relevant for use in austere environments where medical products may be limited and evacuation may be prolonged.
This RFI seeks responses to the barrier combination component of this FoS only.
Although there is an emphasis on use at the point of injury, this capability will likely be used across roles
of care spanning the austere battlefield environment to hospital care settings. The barrier combination product is
expected to be one of many components of the FoS that will provide novel solutions to the DoD and commercial
market with respect to wound care and infection prevention.
The barrier combination product must have the following minimum essential characteristics:
Please refer to Attachment 3 - Minimum Essential Characteristics (MECS)
North American Industry Classification System (NAICS) Code: Unknown
RFI Attachments: The following documents are attached to the RFI
- Attachment 1: Technical Readiness Level (TRL) (Reference Only)
- Attachment 2: Company & Product Information
- Attachment 3: Minimum Essential Characteristics (MECS)
- Response Due Date: Interested parties shall submit the RFI response electronically by 2:00pm Eastern on January 20, 2026, via e-mail to:
Please review Attachments 1, 2, and 3 as well as RFI for BWI PT Barrier Attachment for further instructions
- MEDICAL R & D CONTRACTING DIVISION 2 808 SCHREIDER STREET
- FORT DETRICK , MD 21702
- USA
- Jeanette Collins
- jeanette.m.collins4.civ@health.mil
- Julie Burns
- julia.l.burns3.civ@health.mil
- Dec 03, 2025 11:44 am ESTSources Sought (Original)
With GovernmentContracts, you can:
- Find more opportunities and win more business
- Receive daily alerts for all new bid opportunities
- Get contract opportunities matched to your business